[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universita degli Studi di Genova\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":209},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,70,104,141,166,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636554","pet-guided-resection-in-high-grade-gliomas-100636554",false,"NCT07567196","PET-Guided Resection in High-Grade Gliomas","ResPGlioma: Impact of PET-Guided Resection on Survival in High-Grade Gliomas - A Multicenter Prospective Study","ResPGlioma","Inclusion Criteria:\n\n* age ≥18 years\n* high-grade glioma (WHO grade III\u002FIV) diagnosed on MRI\n* provide written informed consent\n\nExclusion Criteria:\n\n* tumors located in the cerebellum, brainstem, or midline.\n* Patients with medical conditions precluding MRI\n* inability to provide written informed consent\n* secondary high-grade gliomas resulting from malignant transformation of a low-grade glioma\n* other primary malignancy within the past five years","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","Background: Glioblastoma (GBM) is the most common primary brain tumor in adults, with a poor prognosis despite maximal treatment. Current evidence suggests that supramaximal resection, including non-enhancing FLAIR-hyperintense regions, improves survival. However, the extent of FLAIR resection is often limited by functional constraints and its non-specific nature, as it may represent both tumor infiltration and peritumoral edema. This study explores the role of 18F-DOPA PET in refining supramaximal resection by providing a more specific surgical target beyond contrast-enhancing areas.\n\nObjective: To evaluate the impact of 18F-DOPA PET-guided resection on progression-free survival (PFS) and overall survival (OS) in GBM patients, by comparing outcomes between those undergoing PET-RM integrated resection versus conventional MRI-guided resection.\n\nMethods: ResPGlioma is a multicenter, prospective, non-randomized study conducted at IRCCS Ospedale Policlinico San Martino (Genoa) and AOU Città della Salute e della Scienza (Turin). Patients with newly diagnosed, supratentorial, high-grade gliomas undergo preoperative 18F-DOPA PET and MRI. Surgery follows the principle of maximal safe resection, with postoperative MRI at 48 hours assessing the extent of resection (EOR). To confirm PET resection or non-PET resection status, patients will undergo a postoperative 18F-DOPA PET scan at 30 ± 7 days following surgery, prior to the initiation of chemoradiotherapy. Patients are categorized based on EOR criteria (RANO) and PET volume resection (PET-resection vs. PET non-resection). Statistical analyses include Kaplan-Meier survival curves and regression models to identify prognostic factors.Patients are categorized based on EOR criteria (RANO) and PET volume resection (PET-resection vs. PET non-resection). Statistical analyses include Kaplan-Meier survival curves and regression models to identify prognostic factors.\n\nExpected Outcomes: The authors hypothesize that PET-guided resection improves PFS and OS by enabling a more precise tumor removal beyond contrast-enhancing margins while preserving neurological function. Preliminary data support that PET hypercaptant areas contain viable tumor cells and should be resected. This approach may offer a more accessible yet effective alternative to FLAIR-guided supramaximal resection.",[25,26,27,28],"Glioma Glioblastoma Multiforme","Glioma, High Grade","Glioma Surgery","Positron-Emission Tomography(PET)",[30,31,32],"glioma","glioblastoma","PET","RECRUITING","2026-04-27",{"date":36,"type":37},"2026-05-05","ACTUAL",{"date":39,"type":37},"2022-04-01",{"date":41,"type":21},"2029-12-31",{"name":43,"class":44},"Universita degli Studi di Genova","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100629958","tracheostomy-in-delphi-for-intensive-care-trident-100629958","NCT07481435","TRacheostomy in DElphi for iNTensive Care' (TRiDENT)","TRiDENT","Inclusion Criteria:\n\n* A minimum of 5 years of clinical experience treating patients requiring tracheostomy and leadership in the subject area.\n* At least 5 publications in the area.\n\nExclusion Criteria:\n\n* Not more than 70% of the panellists are of the same gender and from each of high and low-middle-income countries",{"count":54,"type":21},40,"The aim of this study is to develop international consensus-based recommendations for tracheostomy care in critically ill patients. Using the Delphi method, the study seeks to identify key practices in post-tracheostomy management, including tube downsizing and decannulation strategies, infection prevention and site care, restoration of communication and swallowing, and the recognition and management of tracheostomy-related complications. By engaging a multidisciplinary panel of international experts involved in tracheostomy care, the study aims to reduce variability in current practice and support the development of standardized, evidence-informed approaches across different clinical settings.",[57,58],"Delphi Process","Delphi Study",[60,61],"Intensive Care Medicine","Post Intensive Care","NOT_YET_RECRUITING",{"date":64,"type":37},"2026-05-04",{"date":66,"type":21},"2026-05-01",{"date":68,"type":21},"2026-12-01",{"name":43,"class":44},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":82,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100600102","rehabilitation-practices-in-critically-ill-patients-receiving-invasive-mechanical-ventilation-in-the-intensive-care-unit-100600102","NCT07093125","Rehabilitation Practices in Critically Ill Patients Receiving Invasive Mechanical Ventilation in the Intensive Care Unit.","An Observational Study on Rehabilitation Practices in the ICU for Critically Ill Patients Undergoing Invasive Mechanical Ventilation - Report (REPOrt)","REPOrt","Inclusion Criteria:\n\n* Patients admitted to a participating ICU\n* Adult patients (aged 16 years or older, depending on local regulations for the definition of \"adults\")\n* Patients who have received invasive ventilation for at least 48 hours\n* Patients who have obtained written informed consent from the patient or next of kin (if local legislation demands so)\n\nExclusion Criteria:\n\n• Patients admitted for withdrawn of life sustain therapy","16 Years","100 Years",{"count":81,"type":21},2400,"28 Days","This international, multicenter, observational study aims to describe rehabilitation practices in Intensive Care Units (ICUs) worldwide.\n\nThe primary objective is to provide an overview of current rehabilitation strategies used in ICUs globally.\n\nSecondary objectives include assessing the relationship between rehabilitation and key ICU outcomes such as ICU and hospital mortality, length of stay, duration of invasive ventilation, extubation failures, and long-term outcomes including quality of life and functional performance 28 days post-ICU discharge.\n\nThe study will also compare rehabilitation practices across different geographic and economic regions to identify potential disparities. The study is structured into three modules, with participation contingent on local resources and feasibility.\n\nThe BASIC Module (mandatory for all centers) gathers fundamental data on rehabilitation practices and their association with patient outcomes.\n\nThe EXTENDED Module (optional) collects more detailed information on the type, timing, duration, and safety of rehabilitation interventions, including passive exercises, active mobilization, respiratory therapies, dysphagia training, occupational therapy, and cognitive support.\n\nThe EXTENDED FOLLOW-UP Module (optional) evaluates the patient's quality of life and functional recovery 28 days after ICU discharge. By examining global rehabilitation practices and their impact on patient outcomes, this study aims to improve rehabilitation strategies in ICUs, contributing to better patient care, recovery, and long-term health outcomes.",[85,86,87,88,89,90,91,92],"Mechanical Ventilation","Pulmonary Rehabilitation","Intensive Care Units (ICUs)","Quality of Life (QOL)","Outcome Assessment","Extubation Failure","Mortality","Critical Care",[94,85,95,96],"Pulmonary rehabilitation","Intensive Care Unit (ICU)","Rehabilitation Outcomes",{"date":64,"type":37},{"date":99,"type":37},"2025-10-01",{"date":101,"type":21},"2029-10-01",{"name":43,"class":44},1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":112,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":103},"100632751","dietary-strategies-for-the-treatment-of-fibromyalgia-in-overweight-and-obese-patients-100632751","NCT07517757","Dietary Strategies for the Treatment of Fibromyalgia in Overweight and Obese Patients","Impact of Different Dietary Strategies in the Management of Overweight and Obesity in Patients With Fibromyalgia: Effects on Pain, Disease Severity, Nutritional and Metabolic Profile, Gut Microbiota and Microbial Metabolites, and Brain GABA and Glutamate Levels","FIBRODIET","Inclusion Criteria:\n\n* Adult female patients with fibromyalgia, aged ≤ 65 years, who are overweight or obese (BMI 24.9 \\\u003C ≤34.9 kg\u002Fm2);\n* Patients able to independently provide their written informed consent to participate in the study;\n* Patients motivated to participate in the project and able to independently manage the dietary plans provided for in the study.\n\nExclusion Criteria:\n\n* Lack of signature on informed consent form\n* Age \\\u003C 18 and \\> 65 years\n* Male gender\n* Patients with food allergies or celiac disease, type 1 diabetes mellitus and autoimmune forms of diabetes mellitus or with severe pancreatic beta cell dysfunction, undergoing treatment with SGLT2 inhibitors, with recent cardiovascular or cerebrovascular events, liver failure, moderate or severe renal failure, respiratory failure, episodes of gout, kidney stones, electrolyte disturbances, NYHA class III-IV heart failure, unstable angina, cardiac arrhythmias or myocardial infarction within the last 12 months, severe depression or any other psychiatric illness, drug, narcotic or alcohol abuse, frail patients, pregnancy and\u002For breastfeeding, patients about to undergo surgery or invasive procedures, rare diseases (porphyria, carnitine deficiency, carnitine palmitoyltransferase, carnitine acylcarnitine translocase and pyruvate carboxylase, mitochondrial beta oxidation disorders), treatment with diuretics.\n* Use of prebiotics and\u002For probiotics not included in the study, or other dietary supplements in the month prior to enrollment\n* Antibiotic treatment less than 3 months prior to enrollment\n* Infections at the time of enrollment or any chronic gastrointestinal disorder (e.g., Crohn's disease)\n* Significant eating problems (e.g., dysphagia).","FEMALE","65 Years",{"count":115,"type":21},90,"INTERVENTIONAL",[118],"NA","Spontaneous, non-sponsored, interventional, controlled, randomized, parallel-arm clinical study.\n\nPrimary objective To assess the impact of specific dietary approaches (ketogenic diet, Mediterranean diet, or Mediterranean diet supplemented with GABA-producing probiotics, e.g., Bifidobacterium adolescentis PRL2019) on fibromyalgia (FM) severity-particularly pain, sleep quality, anxiety, and depression-using validated questionnaires in female patients with FM and overweight\u002Fclass I obesity.\n\nSecondary objectives\n\n* Evaluate effects on anthropometric measures, metabolic profile, and body composition.\n* Assess changes in gut microbiota composition and metabolomic analysis.\n* Measure neurosteroids with positive allosteric activity on GABA-A or NMDA receptors in saliva and\u002For plasma.\n* Exploratory pilot sub-study to quantify brain GABA and glutamate levels through magnetic resonance spectroscopy (MRS) in a subset of patients.\n\nMethods Participants will be recruited from the Rheumatology Unit outpatient clinics of IRCCS Policlinico San Martino Hospital (Genoa). Eligible subjects will be adult women with FM and overweight\u002Fobesity, selected through protocol-defined criteria. Enrollment requires written informed consent.\n\nAt enrollment (baseline), participants will complete validated questionnaires assessing FM severity (pain, sleep quality, depression, anxiety, bowel function). Data collection will include sociodemographic information, Mediterranean diet adherence through PREDIMED questionnaire, basal metabolic rate, medical and dietary history, smoking status, blood pressure, and recent laboratory results. Stool, blood, and saliva samples will be collected for routine tests, metabolomics, and ELISA-based measurement of neuroactive steroids like cortisol, progesterone, DHEA.\n\nWithin 7 days T1, results will be reviewed and eligible participants randomized to one of three groups: hypocaloric ketogenic diet, Mediterranean diet, or Mediterranean diet plus probiotics. Individualized dietary plans will be provided with written and verbal instructions.\n\nAnthropometric measurements (weight, height, BMI, waist circumference, waist-hip ratio) and body composition via bioelectrical impedance analysis BIA will be recorded at T0, T4, T8, and T12, together with biological sample collection.\n\nPilot MRS sub-study A subset of participants will undergo brain GABA and glutamate assessment through MRI spectroscopy performed on a 3T Siemens - Prisma magnet at the baseline, before dietary treatment and after 4 weeks. Results will be compared with spectra from control subjects screened through medical history to exclude relevant diseases.",[121],"Fibromyalgia (FM)",[123,124,125,126,127,128,129,130,131,132],"Fibromyalgia","questionnaires","dietary intervention","obesity","gut microbiota","probiotics","gut-brain-axis","GABA","glutamate","magnetic resonance spectroscopy","2026-04-03",{"date":135,"type":37},"2026-04-08",{"date":137,"type":21},"2026-04",{"date":139,"type":21},"2028-06",{"name":43,"class":44},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":116,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":103},"100600190","protocol-of-the-packer-managing-fatigue-program-versus-standard-information-to-improve-energy-conservation-self-efficacy-in-parkinsons-disease-100600190","NCT07094269","Protocol of the Packer Managing Fatigue Program Versus Standard Information to Improve Energy Conservation Self-Efficacy in Parkinson's Disease","Protocol for a Superiority Randomized Controlled Trial of a Group-Based Fatigue Management Program Versus Standard Information to Improve Self-Efficacy in Energy Conservation in Parkinson's Disease","Inclusion Criteria:\n\n* aged \\>18 years\n* diagnosis of idiopathic Parkinson's disease (PD)\n* Hoehn and Yahr stage ≤3.5\n* Fatigue Severity Scale (FSS) \\>= 4\n\nExclusion Criteria:\n\n* Montreal Cognitive Assessment (MoCA) score \\\u003C22\n* comorbid medical conditions that could independently contribute to fatigue\n* not being fluent in the Italian language\n* Parkinsonism",{"count":149,"type":21},80,[118],"This protocol describes a randomized, controlled, parallel-group, trial evaluating the effectiveness of a group-based fatigue management program for people with Parkinson's disease. The study will be conducted in Italy, with participant recruitment planned to begin on July 1st, 2025. The primary sponsor is the Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal Child Health (DINOGMI) at the University of Genoa, Italy. No external sources of monetary or material support have been declared. The study has received ethical approval from the University of Genoa's Research Ethics Committee (Comitato Etico per la Ricerca di Ateneo - CERA), under protocol number 2025.36, approved on April 3rd, 2025.\n\nThe scientific title of the trial is: Protocol for a Superiority Randomized Controlled Trial of a Group-Based Fatigue Management Program Versus Standard Information to Improve Self-Efficacy in Energy Conservation in Parkinson's Disease\". The public title is: \"Energy Matters: A Protocol of a Randomized Controlled Trial of a Group-Based Fatigue Management Program for People with Parkinson's Disease\".\n\nThe study targets individuals diagnosed with idiopathic Parkinson's disease, experiencing fatigue. Eligible participants must be over 18 years old, present with Hoehn and Yahr stage ≤3.5, and score ≥4 on the Fatigue Severity Scale (FSS). Exclusion criteria include a Montreal Cognitive Assessment (MOCA) score below 21, presence of severe psychiatric comorbidities, medical conditions contributing independently to fatigue, inability to participate in group sessions, or involvement in other structured fatigue management programs.\n\nParticipants will be randomly allocated to one of two arms. The intervention group will attend a six-week Packer Managing Fatigue Program1 Sessions will be conducted in groups of 8-10 participants, led by a licensed occupational therapist. Topics covered include rest, communication, body mechanics, ergonomics, energy-conserving tools, prioritization, lifestyle balance, and goal setting. Sessions will use standardized materials such as participant workbooks2 and visual aids and will take place in appropriately equipped rooms. If a participant is absent from a scheduled group session for personal reasons, the occupational therapist will organize an individual make-up session before the next scheduled group session. This individual session will follow the same content and structure as the missed group session, based on the Packer Managing Fatigue Program. Its purpose is to ensure continuity and fidelity to the intervention, and to allow participants to stay aligned with the group program.\n\nParticipants in the control group will be provided with six fact sheets addressing general information about Parkinson's disease.\n\nThe primary outcome is the change in self-efficacy for performing energy conservation strategies, measured using the Self-Efficacy for Performing Energy Conservation Strategies Assessment (SEPECSA), assessed at baseline, post-intervention, and at a 3-month follow-up.\n\nSecondary outcomes include measures of motor and non-motor symptoms (Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I and II), fatigue severity (Fatigue Severity Scale, Parkinson Fatigue Scale), Fatigue Impact (Modified Fatigue Impact Scale), quality of life (Parkinson Disease Questionnaire-39), participation and autonomy (Impact on Participation and Autonomy questionnaire), psychiatric symptoms (Hospital Anxiety and Depression Scale), and sleep disturbance (Pittsburgh Sleep Quality Index - PSQI). All outcomes will be reassessed immediately and 3 months after the end of the intervention.\n\nThe total planned sample size is 74 participants, with 37 individuals in each study arm.\n\nFor public queries, the contact person is Dr. Elisa Pelosin, Associate Professor at DINOGMI, University of Genoa (email: elisa.pelosin@unige.it). For scientific queries, the reference contact is the University of Genoa's Ethics Committee (email: presidente.cera@unige.it).\n\nAn individual participant data sharing plan is in place. As part of the informed consent process, participants will be asked whether they agree to allow their anonymized data to be shared for future research purposes. Only data from participants who provide explicit consent will be shared. Anonymized individual data will be made available upon reasonable request, in accordance with institutional policies and data protection regulations. Access will be granted by the corresponding author after publication and will remain open for five years",[153],"PARKINSON DISEASE (Disorder)",[155,156,157,158],"occupational therapy","fatigue","parkinson's disease","self-management",{"date":160,"type":37},"2025-10-07",{"date":162,"type":37},"2025-07-01",{"date":164,"type":21},"2026-06-01",{"name":43,"class":44},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":172,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":116,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100598264","effect-of-bio-activation-on-epithelial-and-connective-cell-adhesion-to-titanium-abutments-split-mouth-clinical-trial-100598264","NCT07069231","Effect of Bio-activation on Epithelial and Connective Cell Adhesion to Titanium Abutments: Split Mouth Clinical Trial","Inclusion Criteria:\n\n* presence of at least 4 mm of keratinized mucosa around the implants,\n* patients aged 18 years or older\n* medically healthy patients (ASA I), or patients with mild systemic disease (ASA II)\n* Total or partial edentulous state with space for at least 2 implants\n\nExclusion Criteria:\n\n* ASA physical status 3\n* severe smokers (\\> 10 cig\u002Fday)\n* patients undergoing bisphosphonate therapy\n* pregnant or lactating women\n* estrogen-related hormonal disorders or hormonal substitution therapy patients with a history of head and neck cancers and radiotherapy in this region",true,{"count":174,"type":21},20,[118],"The aim of this \"in vivo\" controlled trial is to assess soft tissue cell adhesion to titanium abutments subjected to different cleaning procedures - no treatment (as they come from the industry), and cleaning by plasma- at an early healing time.\n\nIn fact, the primary aim is Quantity and Quality of soft tissue adhesion at the microscopic level (e.g Fibronectin, Integrin-actin).\n\nThe secondary Aim - Clinical parameters and outcomes - BOP, PPD, MBL (Marginal Bone Level to check influence of plasmapp-treated abutments).\n\nThe null hypothesis of the study was that the cleaning procedure applied to implant abutments has no effect on soft tissue cell adhesion and MBL at an early healing time.",[178],"Missing Tooth\u002FTeeth","2025-07-05",{"date":181,"type":37},"2025-07-16",{"date":183,"type":21},"2025-07-15",{"date":185,"type":21},"2025-10-30",{"name":43,"class":44},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":172,"sex":17,"minAge":194,"maxAge":113,"enrollmentInfo":195,"targetDuration":4,"studyType":116,"phases":196,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":4},"100545177","phase-4-the-effect-of-different-antibiotic-protocols-on-peri-implant-tissue-health-100545177","NCT06378502","The Effect of Different Antibiotic Protocols on Peri-implant Tissue Health","The Effect of Different Antibiotic Protocols for Dental Implant Surgery on Peri-implant Tissue Health and on Oral Microbiome and Resistome","Inclusion Criteria:\n\nHealthy volunteers requiring one single implant or partial implant-supported rehabilitation in an edentulous area of the posterior mandible or maxilla\n\nExclusion Criteria:\n\n* Patients unable to commit to follow-up\n* General contraindications to implant surgery\n* Immuno-suppressed\u002Fimmune-compromised patients\n* Patients irradiated in the head and\u002For neck\n* Uncontrolled diabetes\n* Pregnancy, childbearing potential, breastfeeding\n* Smoking habit\n* Untreated periodontal disease (Caton et al, J Clin Periodontol 2018)\n* Poor oral hygiene and motivation (plaque index \\> 20%)\n* Addiction to alcohol or drugs\n* Psychiatric problems and\u002For unrealistic expectations\n* Patients with an acute infection (abscess) or suppuration in the site intended for implant placement\n* Patients treated or under treatment with intravenous amino-bisphosphonates\n* Patients referred only for implant placement if the follow-up cannot be done at the treatment center\n* Patients participating in other studies, if the present protocol could not be fully adhered to\n* Patients with allergy\u002Fhypersensitivity to penicillin or drug excipients\n* Patients recently treated with antibiotics for other indications","35 Years",{"count":149,"type":21},[197],"PHASE4","The aim of the present project (non-inferiority trial) is to evaluate the effect of different antibiotic strategies (long-span vs. short-span) for implant surgery on peri-implant tissue health, oral microbiome (included resistome) and salivary MiRNomics in healthy patients.",[200],"Antibiotic","2024-04-17",{"date":203,"type":37},"2024-04-22",{"date":205,"type":21},"2024-05-03",{"date":207,"type":21},"2026-06-30",{"name":43,"class":44},""]